mianserin has been researched along with Panic Disorder in 11 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this open label trial was to evaluate mirtazapine tolerability and effectiveness in controlling symptomatology of patients with panic disorder." | 9.10 | Mirtazapine in the treatment of panic disorder: an open-label trial. ( Amore, M; Balista, C; Camardese, G; Carli, V; De Risio, S; Faia, V; Ferrari, G; Poterzio, F; Sarchiapone, M, 2003) |
| "Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder." | 9.09 | Mirtazapine versus fluoxetine in the treatment of panic disorder. ( Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L, 2001) |
| "In this open label pilot study, we studied the efficacy of mirtazapine (Remeron) in panic disorder." | 9.09 | The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. ( Boshuisen, ML; den Boer, JA; Slaap, BR; Vester-Blokland, ED, 2001) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 7.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "The aim of this open label trial was to evaluate mirtazapine tolerability and effectiveness in controlling symptomatology of patients with panic disorder." | 5.10 | Mirtazapine in the treatment of panic disorder: an open-label trial. ( Amore, M; Balista, C; Camardese, G; Carli, V; De Risio, S; Faia, V; Ferrari, G; Poterzio, F; Sarchiapone, M, 2003) |
| "Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder." | 5.09 | Mirtazapine versus fluoxetine in the treatment of panic disorder. ( Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L, 2001) |
| "In this open label pilot study, we studied the efficacy of mirtazapine (Remeron) in panic disorder." | 5.09 | The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. ( Boshuisen, ML; den Boer, JA; Slaap, BR; Vester-Blokland, ED, 2001) |
| "Current studies do not yet provide convincing evidence supporting the efficacy of mirtazapine, reboxetine, milnacipran and duloxetine for the treatment of panic disorder patients." | 4.87 | Novel antidepressants and panic disorder: evidence beyond current guidelines. ( Bellodi, L; Calati, R; Chiesa, A; De Ronchi, D; Perna, G; Serretti, A, 2011) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 3.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serretti, A | 1 |
| Chiesa, A | 1 |
| Calati, R | 1 |
| Perna, G | 1 |
| Bellodi, L | 1 |
| De Ronchi, D | 1 |
| Udo, I | 1 |
| Gash, A | 1 |
| Uguz, F | 1 |
| Sarchiapone, M | 2 |
| Amore, M | 1 |
| De Risio, S | 1 |
| Carli, V | 2 |
| Faia, V | 1 |
| Poterzio, F | 1 |
| Balista, C | 1 |
| Camardese, G | 2 |
| Ferrari, G | 1 |
| Carpenter, LL | 1 |
| Leon, Z | 1 |
| Yasmin, S | 1 |
| Price, LH | 1 |
| Falkai, P | 1 |
| Klesmer, J | 1 |
| Sarcevic, A | 1 |
| Fomari, V | 1 |
| Ribeiro, L | 1 |
| Busnello, JV | 1 |
| Kauer-Sant'Anna, M | 1 |
| Madruga, M | 1 |
| Quevedo, J | 1 |
| Busnello, EA | 1 |
| Kapczinski, F | 1 |
| Boshuisen, ML | 2 |
| Slaap, BR | 2 |
| Vester-Blokland, ED | 1 |
| den Boer, JA | 2 |
| van Roon, AM | 1 |
| Romano, L | 1 |
| DeRisio, S | 1 |
2 reviews available for mianserin and Panic Disorder
| Article | Year |
|---|---|
Novel antidepressants and panic disorder: evidence beyond current guidelines.
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclopropanes; Duloxetine Hydrochloride; Humans; Mi | 2011 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
6 trials available for mianserin and Panic Disorder
| Article | Year |
|---|---|
Mirtazapine in the treatment of panic disorder: an open-label trial.
Topics: Adult; Comorbidity; Depressive Disorder; Female; Histamine H1 Antagonists; Humans; Male; Mianserin; | 2003 |
Clinical experience with mirtazapine in the treatment of panic disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Administration | 1999 |
Mirtazapine versus fluoxetine in the treatment of panic disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Double-Blind Method; Fema | 2001 |
The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period.
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Male; Mianserin; Mirtazapine; Panic Disorde | 2001 |
Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Electrocardiography; Female; Heart Rate; Human | 2002 |
Mirtazapine in the treatment of panic disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Female; Gyrus Cinguli; Hippocampus; Humans; Mal | 2002 |
3 other studies available for mianserin and Panic Disorder
| Article | Year |
|---|---|
Challenges in management of complex panic disorder in a palliative care setting.
Topics: Anti-Anxiety Agents; Anxiety; Breathing Exercises; Comorbidity; Death; Dibenzothiazepines; Eye Movem | 2012 |
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E | 2013 |
Panic attacks during discontinuation of mirtazepine.
Topics: Antidepressive Agents, Tricyclic; Appendectomy; Dysthymic Disorder; Hernia, Umbilical; Humans; Male; | 2000 |